Literature DB >> 26558419

Thrombomodulin as an intravascular safeguard against inflammatory and thrombotic diseases.

Takashi Ito1,2, Yasuyuki Kakihana1, Ikuro Maruyama2.   

Abstract

INTRODUCTION: Thrombomodulin is a transmembrane protein expressed on the surface of endothelial cells. It plays an important role in regulating inflammation as well as coagulation within blood vessels. Recently, a recombinant form of an extracellular fragment of thrombomodulin (rTM) has been developed and is expected to be useful for patients suffering from inflammatory and thrombotic diseases. AREAS COVERED: We initially focus on the physiological and biochemical features of thrombomodulin, including its distribution, structure and function. We then discuss potential therapeutic applications of rTM. EXPERT OPINION: Thrombomodulin exerts anticoagulant and anti-inflammatory effects, in part through activated protein C (APC)-dependent mechanisms. Although recombinant human APC (rhAPC) failed to improve the survival of patients with septic shock and has now been withdrawn from the market, rTM may have some advantages over rhAPC. First, rTM may have less risk of bleeding complications than rhAPC, because rTM needs thrombin to act as an anticoagulant and thus its anticoagulant power can be automatically adjusted by the amount of existing thrombin. Second, the APC-independent actions of rTM might confer benefits, including the suppression of complements, endotoxin (representative pathogen-associated molecular pattern) and high-mobility group box 1 protein (prototypical damage-associated molecular pattern) through the lectin-like domain of rTM.

Entities:  

Keywords:  complement; damage-associated molecular pattern; disseminated intravascular coagulation; pathogen-associated molecular pattern; sepsis; thrombomodulin

Mesh:

Substances:

Year:  2015        PMID: 26558419     DOI: 10.1517/14728222.2016.1086750

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  23 in total

1.  Macrophage-derived HMGB1 as a Pain Mediator in the Early Stage of Acute Pancreatitis in Mice: Targeting RAGE and CXCL12/CXCR4 Axis.

Authors:  Yuhei Irie; Maho Tsubota; Hiroyasu Ishikura; Fumiko Sekiguchi; Yuka Terada; Toshifumi Tsujiuchi; Keyue Liu; Masahiro Nishibori; Atsufumi Kawabata
Journal:  J Neuroimmune Pharmacol       Date:  2017-07-28       Impact factor: 4.147

2.  Anti-inflammatory effect of factor-Xa inhibitors in Japanese patients with atrial fibrillation.

Authors:  Hiromasa Katoh; Tsuyoshi Nozue; Ichiro Michishita
Journal:  Heart Vessels       Date:  2017-03-10       Impact factor: 2.037

3.  A critical role of the Gas6-Mer axis in endothelial dysfunction contributing to TA-TMA associated with GVHD.

Authors:  Miki Furukawa; Xintao Wang; Hiroshi Ohkawara; Masahiko Fukatsu; Lobna Alkebsi; Hiroshi Takahashi; Kayo Harada-Shirado; Akiko Shichishima-Nakamura; Satoshi Kimura; Kazuei Ogawa; Takayuki Ikezoe
Journal:  Blood Adv       Date:  2019-07-23

Review 4.  Perioperative management of patients with atrial fibrillation receiving anticoagulant therapy.

Authors:  Takeshi Omae; Keito Koh; Masateru Kumemura; Sonoko Sakuraba; Yosuke Katsuda
Journal:  J Anesth       Date:  2019-05-08       Impact factor: 2.078

Review 5.  Signaling pathways and intervention therapies in sepsis.

Authors:  Yun-Yu Zhang; Bo-Tao Ning
Journal:  Signal Transduct Target Ther       Date:  2021-11-25

Review 6.  Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient.

Authors:  Miriam Manook; Jean Kwun; Steven Sacks; Anthony Dorling; Nizam Mamode; Stuart Knechtle
Journal:  Transplant Rev (Orlando)       Date:  2018-02-10       Impact factor: 3.943

7.  Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura.

Authors:  Ruinan Lu; Jingrui Sui; X Long Zheng
Journal:  Blood Adv       Date:  2020-11-10

8.  A novel homozygous variant of the thrombomodulin gene causes a hereditary bleeding disorder.

Authors:  Makoto Osada; Keiko Maruyama; Koichi Kokame; Ryunosuke Denda; Kohei Yamazaki; Hisako Kunieda; Maki Hirao; Seiji Madoiwa; Nobuo Okumura; Mitsuru Murata; Yasuo Ikeda; Kentaro Watanabe; Yuiko Tsukada; Takahide Kikuchi
Journal:  Blood Adv       Date:  2021-10-12

9.  Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan.

Authors:  Kazuma Yamakawa; Yutaka Umemura; Mineji Hayakawa; Daisuke Kudo; Masamitsu Sanui; Hiroki Takahashi; Yoshiaki Yoshikawa; Toshimitsu Hamasaki; Satoshi Fujimi
Journal:  Crit Care       Date:  2016-07-29       Impact factor: 9.097

10.  Specific detection of high mobility group box 1 degradation product with a novel ELISA.

Authors:  Takaaki Totoki; Takashi Ito; Shingo Yamada; Goichi Honda; Tsuyoshi Hattori; Ikuro Maruyama
Journal:  Mol Med       Date:  2021-06-09       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.